NeuroPace 2025 Q3 Earnings Revenue Surges 30% Despite Narrowed Losses

NeuroPace (NPCE) delivered mixed results in Q3 2025, , . The company narrowed its net loss to $3.5 million (down 35.9% from $5.45 million in 2024) and raised full-year revenue guidance to $97–$98 million. Analysts highlighted improved gross margins and strategic focus on its core RNS business as key positives.

Revenue

, NeuroPace’s revenue growth outpaced expectations. DIXI product sales, however, declined as the company winds down the line. The ’s strong performance reflects expanding adoption across geographies and Level 4 centers, with gross margins reaching 77.4%.

Earnings/Net Income

, a 42.1% improvement. , sustained losses over six years underscore ongoing financial challenges. The EPS improvement, coupled with positive adjusted EBITDA, signals operational discipline but highlights the need for continued cost management.

Post-Earnings Price Action Review

NeuroPace’s stock surged 11.61% in a single trading day, 28.13% for the week, . , , and strategic clarity. Analysts at Leerink and Cantor Fitzgerald upgraded price targets, . However, mixed earnings estimate revisions and a Zacks Rank #3 (Hold) suggest cautious market sentiment.

CEO Commentary

, , , . . The CEO expressed confidence in RNS’s long-term potential, .

Guidance

. , . , .

Additional News

1. Analyst Upgrades, . .

2. Regulatory Progress, .

3. Strategic Shifts, . .